Skip to content
Toggle main navigation
adMare Community logo
adMare Community logo
      Log in
      Join now
      Select an available language
      EN

      News

      Stay up-to-date on the latest industry news, with access to the most recent and relevant stories from biotechnology, pharmaceutical and life science organizations across Canada.

      Filter by category
      All
      adMare ecosystem
      Industry news
      Life science organizations

      Results (611)

      FELDAN THERAPEUTICS – REPORTS PRELIMINARY PHASE 1 RESULTS FOR FLD-103 IN NODULAR BASAL CELL CARCINOMA, DEMONSTRATING A GENERALLY WELL-TOLERATED SAFETY PROFILE AND SIGNS OF CLINICAL ACTIVITY

      FELDAN THERAPEUTICS – REPORTS PRELIMINARY PHASE 1 RESULTS FOR FLD-103 IN NODULAR BASAL CELL CARCINOMA, DEMONSTRATING A GENERALLY WELL-TOLERATED SAFETY PROFILE AND SIGNS OF CLINICAL ACTIVITY

      FLD-103 was generally well tolerated across all dose cohorts; no maximum tolerated dose was reached.Preliminary Phase 1 data suggest signs of clinical activity in exploratory assessments, with a reduction of more than 30% in tumor tissue compared with baseline observed in 28 of 32 treated lesions (88%). Of these, 20 showed a reduction of more than 50%, including 6 lesions with a complete histologi
      November 19, 2026
      World AMR Awareness Week 2026

      World AMR Awareness Week 2026

      This #WorldAMRAwarenessWeek, we’re highlighting the urgent need to address antimicrobial resistance (AMR), a growing threat to patients in Canada and around the world. A recent report by the @Council of Canadian Academies estimated that 26%, or about 1 in 4 infections in Canada are already resistant to the drugs generally used to treat them, and 5,400 people die each year due to AMR infections. As
      November 19, 2026
      BIOTECanada President & CEO Wendy Zatylny discusses the Pharmaceutical and Life Sciences Sector Task Force recommendations

      BIOTECanada President & CEO Wendy Zatylny discusses the Pharmaceutical and Life Sciences Sector Task Force recommendations

      In a new Hill Times article, BIOTECanada President & CEO Wendy Zatylny discusses the Pharmaceutical and Life Sciences Sector Task Force recommendations, and the need for timely action on investment, regulatory modernization and a coordinated Life Sciences Industrial Strategy.Read the full article here
      November 16, 2026
      Medicenna – Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026

      Medicenna – Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026

      Median overall survival (mOS) was 13.7 months with a single high-dose treatment with bizaxofusp vs. 6.2 months for an eligibility-matched and propensity score-balanced external control arm (ECA) in a Phase 3 relevant unresectable IDH-wildtype recurrent glioblastoma (rGBM) patients (N = 19, HR 0.499; p=0.013)Survival favored bizaxofusp with statistical significance versus ECA across the full per-pr
      November 16, 2026
      Statement on World Diabetes Day

      Statement on World Diabetes Day

      Today on #WorldDiabetesDay, we recognize the more than 4 million Canadians living with diabetes and the importance of earlier detection, consistent care, and stronger support for Canadian patients.This year’s call to #ActEarlyOnDiabetes is a reminder of the urgency. With 853 million people worldwide projected to be living with diabetes by 2050, taking action earlier can improve patient health outc
      November 14, 2026
      Epitopea – Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer

      Epitopea – Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer

      CAMBRIDGE, UK and MONTREAL, Nov. 09, 2026 (GLOBE NEWSWIRE) — Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed in OVACT, its first-in-human Phase 1/1b clinical trial evaluating its lead program, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer (HGSOC).OVACT i
      November 9, 2026
      Federal Budget Builds on Momentum for Canada’s Life Sciences Sector

      Federal Budget Builds on Momentum for Canada’s Life Sciences Sector

      OTTAWA – BIOTECanada welcomes measures in Budget 2026 that can help strengthen Canada’s life sciences sector, including expanded support for research and development, new investment incentives and additional funding for strategic sectors, including biomanufacturing.“Expanding SR&ED eligibility to include certain regulatory approval and intellectual property costs is an important step for biotechno
      November 6, 2026
      GlycoNet – Global Scientific Community Unveils Roadmap to Advance the Next Frontier of Bio-Innovation

      GlycoNet – Global Scientific Community Unveils Roadmap to Advance the Next Frontier of Bio-Innovation

      Supported by Canada’s GlycoNet and developed with contributions from more than 100 scientists worldwide, the roadmap calls for coordinated international action to accelerate the impact of glycomics in healthcare, food security, sustainable materials, and the global bioeconomy.EDMONTON, AB (November 4, 2026) – Scientists across five continents have collaborated to develop a global roadmap outlining
      November 4, 2026
      Thryv Therapeutics – Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Long QT Syndrome Efficacy Cohort Fully Enrolled

      Thryv Therapeutics – Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Long QT Syndrome Efficacy Cohort Fully Enrolled

      $30 million Series B financing led by InClin, Inc., a global contract research organization, with continued support from existing investorsASPIRE-HF, a Phase 2a study of THRV-1268 in heart failure with reduced ejection fraction and QTc prolongation, opens for enrollment in early 2027Wave II, a Phase 2/3 study of THRV-1268 in Long QT Syndrome, completes enrollment of its first efficacy cohort, with
      November 3, 2026
      GSK – Hibsago (bepirovirsen) approved in Canada as the first and only finite therapy indicated to achieve functional cure of chronic hepatitis

      GSK – Hibsago (bepirovirsen) approved in Canada as the first and only finite therapy indicated to achieve functional cure of chronic hepatitis

      Hibsago was reviewed under Health Canada’s Priority Review policy, reflecting its innovation and potential to address a disease with high unmet medical needApproval is based on data from Phase III B-Well trials which demonstrated significant and clinically meaningful functional cure ratesAn estimated 262,000 people in Canada live with chronic hepatitis B1, a leading cause of liver cancer2MISSISSAU
      November 3, 2026
      Roche Canada – Health Canada approves (Pr)Ocrevus® (ocrelizumab) for treating pediatric relapsing-remitting multiple sclerosis

      Roche Canada – Health Canada approves (Pr)Ocrevus® (ocrelizumab) for treating pediatric relapsing-remitting multiple sclerosis

      The intravenous formulation of Ocrevus (Ocrevus IV) addresses a critical need in pediatric multiple sclerosis (MS) as a treatment option for children as young as 10 years old. In the Phase III OPERETTA 2 study, Ocrevus IV demonstrated non-inferiority in relapse control and a statistically significant reduction in brain lesions compared to fingolimod,[1] which is the only other approved treatment f
      November 3, 2026
      Specific Biologics – Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS

      Specific Biologics – Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS

      Financing led by Hatteras Venture Partners, with participation from foundational investors Lumira Ventures and adMare BioInnovations and a new syndicate of life sciences investors Proceeds will be used to advance lead Dualase® therapeutic candidate through initial clinical biomarker proof-of-concept in patients with C9ORF72-associated ALSGene-editing platform designed to precisely remove disease-c
      November 2, 2026
      BIOTECanada Welcomes Recognition of Biotechnology as a Strategic Canadian Capability

      BIOTECanada Welcomes Recognition of Biotechnology as a Strategic Canadian Capability

      BIOTECanada welcomes the federal government’s recognition of biotechnology and pharmaceuticals as strategic capabilities in Canada’s new National Security Strategy. This is an important step in recognizing the role biotechnology plays in Canada’s health, economy, security and sovereignty.Across the country, BIOTECanada members are developing new therapies, vaccines, technologies, advancing manufac
      November 2, 2026
      BIOTECanada Strengthens Canada–Korea Biotechnology Collaboration at BIX 2026

      BIOTECanada Strengthens Canada–Korea Biotechnology Collaboration at BIX 2026

      BIOTECanada was pleased to be a part of the Canadian delegation attending BIX 2026 in Seoul, where Canada was named the official Country of Honour.During the visit, BIOTECanada President & CEO, Wendy Zatylny signed a Memorandum of Understanding with KoreaBIO to support closer collaboration between the Canadian and Korean biotechnology and life sciences sectors.The agreement will support opportunit
      October 29, 2026
      Korea’s Leading Biotech and Pharmaceutical Convention BIX 2026 Opens in Seoul with 300+ Companies and 600 Booths

      Korea’s Leading Biotech and Pharmaceutical Convention BIX 2026 Opens in Seoul with 300+ Companies and 600 Booths

      by Sung, Jae Jun BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), a leading biotechnology and pharmaceutical convention, opened at COEX in Seoul on October 28. Hosted by Korea Biotechnology Industry Organization (KoreaBIO), this year’s event runs through October 30 under the theme “Real Innovation Glows in the Dark.” Over three days, BIX 2026 brings together technologies, market insights, and industry sta
      October 29, 2026
      BIOTECanada Statement: Federal Government Moves Forward on Venture and Growth Capital

      BIOTECanada Statement: Federal Government Moves Forward on Venture and Growth Capital

      BIOTECanada welcomes the federal government’s latest steps to strengthen Canada’s venture and growth capital market, including moving forward with the Venture and Growth Capital Catalyst Initiative (Growth VCCI) and outlining how its new $750 million Early and Growth Stage Investment Strategy will be allocated.As our members advance science, develop new therapies and technologies, and build compan
      October 26, 2026
      BIOTECanada Consultation on a proposed interim approach to speed up the review of certain pediatric drugs

      BIOTECanada Consultation on a proposed interim approach to speed up the review of certain pediatric drugs

      October 23, 2026Bureau of Policy, Science and International ProgramsPharmaceutical Drugs DirectorateHealth Products and Food BranchHealth CanadaEmail: [email protected]. Comments on Consultation on a proposed interim approach to speed up the review of certain pediatric drugsDear Health Canada,On behalf of the two hundred member companies of BIOTECanada, I am writing regarding H
      October 23, 2026
      BIOTECanada welcomes the federal government’s new Cabinet Directive onRegulatory Competitiveness and Red Tape Reduction

      BIOTECanada welcomes the federal government’s new Cabinet Directive onRegulatory Competitiveness and Red Tape Reduction

      Regulatory modernization has been a consistent focus of BIOTECanada’s advocacy,including in our federal budget recommendations. The directive’s emphasis on reducingunnecessary burden and improving regulatory alignment is consistent with our call for amore predictable and efficient regulatory system.Around the world, countries are racing to reshape their economies and attract theinvestment needed t
      October 22, 2026
      Important progress for Canada’s rare disease community!

      Important progress for Canada’s rare disease community!

      BIOTECanada welcomes the federal government’s commitment to ongoing $500 million annual funding for the National Strategy for Drugs for Rare Diseases and to continued collaboration with provincial and territorial partners.Phase I established an important foundation, demonstrating collaboration between federal, provincial and territorial partners to address the needs of rare disease patients across
      October 20, 2026
      Canada’s life sciences strength is capturing global attention

      Canada’s life sciences strength is capturing global attention

      Read the article below:Bio-Europe Autumn Supplement 2026: Featured on Pages 26-27
      October 15, 2026
      Contact
      adMare BioInnovations

      Canada

      thansen@admarebio.com
      Cookies
      Reselect cookie settings
      Community engagement platform by Hivebrite.